vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Safehold Inc. (SAFE). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $97.9M, roughly 1.4× Safehold Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 28.5%, a 7.0% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 6.5%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 2.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.
ADMA vs SAFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $97.9M |
| Net Profit | $49.4M | $27.9M |
| Gross Margin | 63.8% | 98.6% |
| Operating Margin | 45.1% | 27.4% |
| Net Margin | 35.5% | 28.5% |
| Revenue YoY | 18.4% | 6.5% |
| Net Profit YoY | -55.9% | 7.1% |
| EPS (diluted) | $0.20 | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $97.9M | ||
| Q3 25 | $134.2M | $96.2M | ||
| Q2 25 | $122.0M | $93.8M | ||
| Q1 25 | $114.8M | $97.7M | ||
| Q4 24 | $117.5M | $91.9M | ||
| Q3 24 | $119.8M | $90.7M | ||
| Q2 24 | $107.2M | $89.9M | ||
| Q1 24 | $81.9M | $93.2M |
| Q4 25 | $49.4M | $27.9M | ||
| Q3 25 | $36.4M | $29.3M | ||
| Q2 25 | $34.2M | $27.9M | ||
| Q1 25 | $26.9M | $29.4M | ||
| Q4 24 | $111.9M | $26.0M | ||
| Q3 24 | $35.9M | $19.3M | ||
| Q2 24 | $32.1M | $29.7M | ||
| Q1 24 | $17.8M | $30.7M |
| Q4 25 | 63.8% | 98.6% | ||
| Q3 25 | 56.3% | 98.5% | ||
| Q2 25 | 55.1% | 99.1% | ||
| Q1 25 | 53.2% | 98.8% | ||
| Q4 24 | 53.9% | 98.8% | ||
| Q3 24 | 49.8% | 98.8% | ||
| Q2 24 | 53.6% | 98.8% | ||
| Q1 24 | 47.8% | 98.8% |
| Q4 25 | 45.1% | 27.4% | ||
| Q3 25 | 38.0% | 25.9% | ||
| Q2 25 | 35.1% | 25.5% | ||
| Q1 25 | 30.4% | 25.9% | ||
| Q4 24 | 32.6% | 24.6% | ||
| Q3 24 | 33.1% | 17.5% | ||
| Q2 24 | 36.6% | 26.7% | ||
| Q1 24 | 26.7% | 26.4% |
| Q4 25 | 35.5% | 28.5% | ||
| Q3 25 | 27.1% | 30.5% | ||
| Q2 25 | 28.1% | 29.8% | ||
| Q1 25 | 23.4% | 30.1% | ||
| Q4 24 | 95.2% | 28.3% | ||
| Q3 24 | 30.0% | 21.3% | ||
| Q2 24 | 29.9% | 33.0% | ||
| Q1 24 | 21.7% | 33.0% |
| Q4 25 | $0.20 | $0.38 | ||
| Q3 25 | $0.15 | $0.41 | ||
| Q2 25 | $0.14 | $0.39 | ||
| Q1 25 | $0.11 | $0.41 | ||
| Q4 24 | $0.45 | $0.36 | ||
| Q3 24 | $0.15 | $0.27 | ||
| Q2 24 | $0.13 | $0.42 | ||
| Q1 24 | $0.08 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $21.7M |
| Total DebtLower is stronger | $72.1M | $4.6B |
| Stockholders' EquityBook value | $477.3M | $2.4B |
| Total Assets | $624.2M | $7.2B |
| Debt / EquityLower = less leverage | 0.15× | 1.90× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $21.7M | ||
| Q3 25 | $61.4M | $12.1M | ||
| Q2 25 | $90.3M | $13.9M | ||
| Q1 25 | $71.6M | $17.3M | ||
| Q4 24 | $103.1M | $8.3M | ||
| Q3 24 | $86.7M | $15.6M | ||
| Q2 24 | $88.2M | $13.4M | ||
| Q1 24 | $45.3M | $11.3M |
| Q4 25 | $72.1M | $4.6B | ||
| Q3 25 | $72.4M | $4.5B | ||
| Q2 25 | — | $4.4B | ||
| Q1 25 | — | $4.3B | ||
| Q4 24 | $72.3M | $4.3B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.2B | ||
| Q1 24 | — | $4.1B |
| Q4 25 | $477.3M | $2.4B | ||
| Q3 25 | $431.2M | $2.4B | ||
| Q2 25 | $398.3M | $2.4B | ||
| Q1 25 | $373.4M | $2.4B | ||
| Q4 24 | $349.0M | $2.3B | ||
| Q3 24 | $231.9M | $2.3B | ||
| Q2 24 | $188.3M | $2.3B | ||
| Q1 24 | $153.7M | $2.3B |
| Q4 25 | $624.2M | $7.2B | ||
| Q3 25 | $568.7M | $7.1B | ||
| Q2 25 | $558.4M | $7.1B | ||
| Q1 25 | $510.6M | $6.9B | ||
| Q4 24 | $488.7M | $6.9B | ||
| Q3 24 | $390.6M | $6.8B | ||
| Q2 24 | $376.4M | $6.8B | ||
| Q1 24 | $350.9M | $6.7B |
| Q4 25 | 0.15× | 1.90× | ||
| Q3 25 | 0.17× | 1.89× | ||
| Q2 25 | — | 1.87× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | 0.21× | 1.84× | ||
| Q3 24 | — | 1.88× | ||
| Q2 24 | — | 1.81× | ||
| Q1 24 | — | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $47.8M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $47.8M | ||
| Q3 25 | $13.3M | $-1.4M | ||
| Q2 25 | $21.1M | $28.0M | ||
| Q1 25 | $-19.7M | $8.9M | ||
| Q4 24 | $50.2M | $37.9M | ||
| Q3 24 | $25.0M | $8.3M | ||
| Q2 24 | $45.6M | $24.8M | ||
| Q1 24 | $-2.2M | $-3.1M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | 1.72× | ||
| Q3 25 | 0.36× | -0.05× | ||
| Q2 25 | 0.62× | 1.00× | ||
| Q1 25 | -0.73× | 0.30× | ||
| Q4 24 | 0.45× | 1.45× | ||
| Q3 24 | 0.70× | 0.43× | ||
| Q2 24 | 1.42× | 0.83× | ||
| Q1 24 | -0.12× | -0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
